Differences in survivin location and Bcl-2 expression in CD30+ lymphoproliferative disorders of the skin compared with systemic anaplastic large cell lymphomas: an immunohistochemical study.

Abstract

BACKGROUND:

Cutaneous CD30+ lymphoproliferative disorders (LPDs) are a spectrum of disease associated with a favourable prognosis. Systemic anaplastic large cell lymphoma (ALCL), although morphologically and phenotypically similar, differs in clinical presentation and has a less favourable biological behaviour. Dysregulation of apoptosis, the process regulating cell population by programmed death, can explain the differences among these disorders.

OBJECTIVES:

We investigated the expression of two inhibitors of apoptosis, survivin and Bcl-2 protein, in serial skin lesion samples from CD30+ LPDs compared with systemic ALCL.

METHODS:

Immunohistochemical analysis with antibodies against anaplastic lymphoma kinase (ALK)-1 protein, survivin and Bcl-2 protein was performed in 10 cutaneous CD30+ LPDs (five lymphomatoid papulosis, five ALCL) and 18 systemic ALCLs. Reverse transcription-polymerase chain reaction studies for ALK and ALK/nucleophosmin were also performed.

RESULTS:

Cutaneous CD30+ LPDs shared a heterogeneous expression of cytoplasmic survivin with all systemic ALCLs, and of Bcl-2 with systemic ALK- ALCLs; however, they differ from systemic ALK- ALCLs because they lack nuclear survivin (P = 0.045), and from systemic ALK+ ALCLs by a higher expression of Bcl-2 (P = 0.045) and a lack of ALK-1. Overall, coexpression of Bcl-2 and nuclear survivin in CD30+ LPDs was associated with a less favourable disease survival.

CONCLUSIONS:

The different patterns of expression of Bcl-2 and survivin in CD30+ LPDs might have an impact on their different biological and clinical behaviour. Moreover, nuclear localization of survivin, similarly to ALK, may be a useful marker for predicting a systemic form of ALCL with cutaneous presentation.

• Authors: G Goteri, O Simonetti, S Rupoli, G Piccinini, C Rubini, D Stramazzotti, F Fazioli, C Capomagi, P Leoni, A M Offidani, L Lo Muzio, L Lomuzio
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 157 Issue 1 Pg. 41-8 (Jul 2007) ISSN: 0007-0963 [Print] England
• PMID: 17484779 (Publication Type: Comparative Study, Journal Article)

Chemical References

• BIRC5 protein, human
• Cysteine Proteinase Inhibitors
• Inhibitor of Apoptosis Proteins
• Ki-1 Antigen
• Microtubule-Associated Proteins
• Neoplasm Proteins
• Proto-Oncogene Proteins c-bcl-2
• Survivin
• ALK protein, human
• Anaplastic Lymphoma Kinase
• Protein-Tyrosine Kinases
• Receptor Protein-Tyrosine Kinases

Topics

• Adult
• Aged
• Aged, 80 and over
• Anaplastic Lymphoma Kinase
• Cysteine Proteinase Inhibitors (pharmacology)
• Diagnosis, Differential
• Female
• Humans
• Immunohistochemistry (methods)
• Inhibitor of Apoptosis Proteins
• Ki-1 Antigen (metabolism)
• Lymphoma, Large B-Cell, Diffuse (diagnosis)
• Lymphoproliferative Disorders (diagnosis)
• Male
• Microtubule-Associated Proteins (metabolism)
• Middle Aged
• Neoplasm Proteins (metabolism)
• Protein-Tyrosine Kinases (metabolism)
• Proto-Oncogene Proteins c-bcl-2 (metabolism)
• Receptor Protein-Tyrosine Kinases
• Skin
• Skin Neoplasms (diagnosis)
• Survivin